Drug Trial Radar · NCT00855738
A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
Last checked: Nov 19, 2026Latest source record: Jan 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
May 2007
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 4, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and topiramate, used as first-choice combination therapy (bitherapy) in patients with focal epilepsy.
Conditions
- Focal Epilepsy
Interventions
Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, ZonisamideDrug
* Gabapentin: up to 3.600 mg/d * Lamotrigine: up to 400 mg/d * Levetiracetam: up to 3.000 mg/d * Pregabalin: up to 600 mg/d * Oxcarbazepine: up to 2.400 mg/d * Tiagabine: up to 30 mg/d * Topiramate: up to 400 mg/d * Zonisamide: up to 500 mg/d
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Participants Classified as RespondersTime frame: Baseline, Month 3, Month 6 (last 3 months of treatment)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.